Ruxolitinib in acute and chronic graft-versus-host disease: real life long-term experience in a multi-center study for adult and pediatric patients, on behalf of the GETH-TC
Por:
Escamilla-Gómez V, García Gutiérrez V, Alcalde-Mellado P, Astibia-Mahillo B, Chinea-Rodriguez A, López-Corral L, Acera-Gómez M, Torres Ochando MK, Borrero Borrego A, González Pinedo L, Zudaire Ripa T, González Vicent M, Benzaquén A, Izquierdo Garcia I, Asensi Cantó P, Montoro J, Martín-Domínguez FM, Orti G, Valcárcel D, Benitez-Carabante MI, Diaz-de-Heredia C, Cañamero E, Ferrá C, García-Cadenas I, Redondo S, Sisinni L, Perez-Martínez A, Mussetti A, Garcia-Mañó L, Palomo-Moraleda MDP, González-Sierra PA, Jurado M and Perez-Simon JA
Publicada:
1 mar 2025
Ahead of Print:
1 dic 2024
Resumen:
Ruxolitinib has been approved for the treatment of adults and pediatric patients >= 12 years with steroid refractory graft-versus-host disease (GvHD). However, real-life studies are needed to confirm the results of clinical trials and further assess its efficacy in special populations. We performed a descriptive, retrospective, multi-center study of 352 adults and 42 pediatric patients treated with ruxolitinib for steroid-refractory acute or chronic GvHD. Among 119 and 233 adult patients with acute and chronic GvHD, overall response rate (ORR) was 58.8% (CR 33.6%) and 65.7% (CR 18.5%), respectively. Corticosteroids were withdrawn in 59.2% and 40.1%, and ruxolitinib in 47.2% and 34.8% in the acute and chronic groups of responders. Among 29 and 13 pediatric patients with acute and chronic GvHD, ORR was 82.7% (CR 51.7%) and 100% (CR 23%), respectively. Among responder patients, corticosteroids were withdrawn in 72.7% and 50%, and ruxolitinib in 75% and 30.7% in both groups respectively. Ruxolitinib in the real world setting, showed similar results as compared to clinical trials. Its efficacy is maintained in subsequent lines of treatment. In the pediatric population, the data are more favorable. In the long-term follow-up, corticosteroids, ruxolitinib and other inmunosuppressive drugs could be eliminated in a remarkably proportion of patients.
Filiaciones:
Escamilla-Gómez V:
Servicio de hematologia, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS)/CSIC, Universidad de Sevilla, Sevilla, Spain
García Gutiérrez V:
Hematology Service, Hospital Universitario Ramón y Cajal. IRYCIS, Universidad de Alcalá, Madrid, Spain
Alcalde-Mellado P:
Servicio de hematologia, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS)/CSIC, Universidad de Sevilla, Sevilla, Spain
Astibia-Mahillo B:
Hematology Service, Hospital Universitario Ramón y Cajal. IRYCIS, Universidad de Alcalá, Madrid, Spain
Chinea-Rodriguez A:
Hematology Service, Hospital Universitario Ramón y Cajal. IRYCIS, Universidad de Alcalá, Madrid, Spain
López-Corral L:
Department of Hematology, Hospital Clínico Universitario de Salamanca (CAUSA/IBSAL), Salamanca, Spain
Acera-Gómez M:
Department of Hematology, Hospital Clínico Universitario de Salamanca (CAUSA/IBSAL), Salamanca, Spain
Torres Ochando MK:
Hematology Department, Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain
Borrero Borrego A:
Hematology Department, Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain
González Pinedo L:
Hematology Department, Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain
Zudaire Ripa T:
Hematology Department, Hospital Universitario de Navarra, Pamplona, Spain
González Vicent M:
Hematopoietic Transplant Department, Hospital Universitario Niño Jesús, Madrid, Spain
Benzaquén A:
Hematology Department, Hospital Clínico Universitario de Valencia, Instituto de Investigación Sanitaria INCLIVA, Valencia, Valencia, Spain
Izquierdo Garcia I:
Hematology Department, Hospital Universitario Miguel Servet, Zaragoza, Spain
Asensi Cantó P:
Hematology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain
Montoro J:
Hematology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain
Martín-Domínguez FM:
Servicio de hematologia, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS)/CSIC, Universidad de Sevilla, Sevilla, Spain
Orti G:
Hematology Department, HospitalUniversitario Vall d´Hebron, Barcelona, Spain
Valcárcel D:
Hematology Department, HospitalUniversitario Vall d´Hebron, Barcelona, Spain
Benitez-Carabante MI:
Hematology and Oncology Department, Division of Pediatric Hematology and Oncology, Hospital Universitario Vall d´Hebron, Barcelona, Spain
Diaz-de-Heredia C:
Hematology and Oncology Department, Division of Pediatric Hematology and Oncology, Hospital Universitario Vall d´Hebron, Barcelona, Spain
Cañamero E:
Hematology Deparment, HospitalUniversitario Germans Trias i Pujol - Institut Català d'Oncologia, Barcelona, Spain
:
Hematology Deparment, HospitalUniversitario Germans Trias i Pujol - Institut Català d'Oncologia, Barcelona, Spain
García-Cadenas I:
Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Redondo S:
Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Sisinni L:
Hemato-Oncology Pediatric Service, HospitalUniversitario La Paz, Madrid, Spain
Perez-Martínez A:
Hemato-Oncology Pediatric Service, HospitalUniversitario La Paz, Madrid, Spain
Mussetti A:
Department of Hematology, Hospital Duran i Reynals, Instituto Catalán de Oncología, L'Hospitalet De Llobregat, Barcelona, Spain
Garcia-Mañó L:
Hospital Universitario Son Espases, Islas Baleares, Spain
Palomo-Moraleda MDP:
Hematology Department, Hospital Universitario Central de Asturias, Oviedo, Spain
González-Sierra PA:
Hospital Universitario Virgen de las Nieves, Instituto de Investigación Biosanitaria, Granada, Spain
Jurado M:
Hospital Universitario Virgen de las Nieves, Instituto de Investigación Biosanitaria, Granada, Spain
Perez-Simon JA:
Servicio de hematologia, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS)/CSIC, Universidad de Sevilla, Sevilla, Spain
|